The Rheumatologist
COVID-19 News
You are here: Home / Articles / Optical Workings: Specialists Must Communicate to Treat Eye Disease

Optical Workings: Specialists Must Communicate to Treat Eye Disease

• By

Richard Quinn is a freelance writer in New Jersey.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. AbbVie Inc. News release: AbbVie’s HUMIRA (adalimumab) receives U.S. Food and Drug Administration approval to treat adults with non-infectious intermediate, posterior and panuveitis. 2016 Jun 30.
  2. AbbVie Inc. News release: AbbVie receives orphan drug designation for Humira (adalimumab) from the U.S. Food and Drug Administration for the investigational treatment of certain forms of non-infectious uveitis. 2014 May 20.

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »